Pluripotent stem cells (PSCs) are self-renewing stem cells with the ability to differentiate into all cell types of the embryo proper. They can give rise to all cell types derived from the germ layers ectoderm, mesoderm and endoderm, a property known as pluripotency.Their enormous developmental potential makes PSCs prime candidates for applications in regenerative medicine, where lineage-specific progeny cells are used to replace degenerated or diseased cells and tissues (PMID: 24434846). PSCs are also a powerful tool for studying human diseases and development. PSC differentiation in vitro can partially recapitulate human development in vivo. Comparing PSCs from healthy and diseased donors can provide insights into the pathology of human diseases and, in combination with modern genome editing techniques, opens the possibility of modeling disease-specific lesions. Finally, PSCs have opened new avenues for drug and toxicity screening (PMID: 23746976).
Based on their origin, pluripotent stem cells can be classified as human embryonic stem (ES) cells or induced pluripotent stem (iPS) cells.
Human embryonic stem cells are derived from the inner cell mass of a developing human embryo and were isolated for the first time in 1998 by James Thomson (PMID: 9804556). Use of ES cells is controversial because their derivation involves the destruction of a human embryo, and many countries have imposed restrictions on their de novo generation and use, such as the regulation of stem cell research in Europe.
Induced pluripotent stem cells are derived from somatic cells via somatic cell reprogramming. Due to their somatic origin, their use is viewed as ethically less problematic. For details about reprogramming, see the section below: 4 Somatic cell reprogramming.Both cell types grow as cell lines that form characteristic adherent colonies. In terms of morphology, marker expression, developmental potential, and experimental handling, ES and iPS cells are essentially indistinguishable.
Miltenyi Biotec has created dedicated application protocols to maintain and cryopreserve pluripotent stem cell lines.
In 2006, Takahashi and Yamanaka reported the reprogramming of somatic cells to a pluripotent state using defined transcription factors (PMID: 16904174). iPS cells have since become an invaluable tool for strategies in basic developmental research, disease modeling, drug discovery, and regenerative medicine.
Several methodologies have been developed for the de novo generation of iPS cells (PMID: 26883003). The webinar in the Related Resources panel to the right offers an overview of reprogramming methods.Miltenyi Biotec offers clinically relevant reprogramming tools for iPS cell generation based on non-integrative mRNA transfection technology. mRNA reprogramming has the highest efficiency among all current technologies (>1 %) and is the safest and fastest method for the de novo generation of iPS cell lines (PMID:25437882). Somatic cell types amenable to reprogramming with this technique include human fibroblasts, endothelial progenitors, and renal epithelial cells.
At a glance: Kits and reagents for the generation of a fibroblast culture
|Tissue dissociation||Whole Skin Dissociation Kit, human|
Magnetic cell separation offers an effective and fast means of isolating reprogrammed iPS cells to establish new iPS cell lines. Traditionally, iPS cells are isolated by picking individual colonies, which assumes that each colony represents a single reprogramming event and enables derivation of a clonal, genetically homogeneous cell population. Live cell staining antibodies for the pluripotency markers TRA-1-60 or TRA-1-81 can assist identifying and picking reprogrammed colonies, but this method is nonetheless labor-intensive and requires experience in identifying reprogrammed colonies and transferring them to a new culture dish.With magnetic cell separation, reprogrammed cells can be isolated in bulk (PMID: 23734247). Multiple cell lines can be processed simultaneously, generating large amounts of cells in a short time, and the process can be automated. Furthermore, bulk cells can be subjected to subcloning, if clonal cultures are required. For details on MACS® Cell Separation Technology, see the MACS Handbook chapter Magnetic Cell Separation.
At a glance: Kits and reagents for the separation of reprogrammed iPS cells
|Starting material||Isolation strategy||Comments||Automation||Product|
|Single-cell suspension of cell culture||Positive selection of target cells||Yes||Anti-TRA-1-60 MicroBeads, human|
|Single-cell suspension of cell culture||Positive selection of target cells||Yes||Anti-SSEA-4 MicroBeads, human|
|Single-cell suspension of cell culture||Depletion of non-target cells||Removal of fibroblasts||Yes||Anti-Fibroblast MicroBeads, human|
MACS Cell Separation Technology offers an easy way to purify reprogrammed iPS cells based on pluripotency markers such as TRA-1-60 or SSEA-4 (PMID: 21637193, 26281015). Alternatively, isolation can also be achieved by depleting unwanted fibroblasts (PMID: 26237226) using the Anti-Fibroblast MicroBeads, human.An article describing the magnetic isolation iPS cells after reprogramming can be downloaded from the Related Resources panel to the right.
Propagation of pluripotent stem cells requires special attention and qualified reagents to maintain their pristine features. Different basic cultivation principles have been developed over time and have different advantages and disadvantages.A webinar describing the different cultivation systems for PSCs can be accessed from the Related Resources panel to the right.
At a glance: Kits and reagents for the removal of feeder cells from cocultures with PSCs
Depletion of feeder cells by magnetic cell separation. Mouse embryonic fibroblasts (MEFs) were depleted from a coculture with mouse embryonic stem cells using Feeder Removal MicroBeads, mouse, an LS Column, and a MidiMACS™ Separator. Flow cytometric analysis with CD15 (SSEA-1)-APC and Anti-Feeder-PE on the MACSQuant® Analyzer indicates that a starting population of 10 % MEFs was completely removed. The purity of the enriched ES cells was about 99.9 %.
At a glance: Kits and reagents for feeder-free culture of PSCs
As PSCs move closer to clinical applications, alternatives to coculture with feeder cells eliminate the qualification and risk assessment required for feeder cells as additional components of a culture system. The first culture system for feeder-free propagation of PSCs was described in 2006 (PMID: 16862139), and has since been refined by reducing the number of components (PMID: 21478862).
Miltenyi Biotec developed a media formulation that combines robustness and reproducibility with a reduced number of components suitable for GMP-grade production. The research-grade StemMACS™ iPS-Brew XF and GMP-grade iPS-Brew GMP Medium enable a seamless transition from basic research to manufacturing for cell therapy applications.
Feeder-free culture systems replace the feeder layer with a coating matrix that facilitates cell attachment. Various extracellular matrices are used, including Matrigel® and its derivatives, which have components of animal origin, and vitronectin or Laminin-521, which are recombinant, chemically defined matrices (PMID: 24463987). StemMACS iPS-Brew XF can be combined with any commonly used matrix, but Laminin-521 is recommended because it maintains the xeno-free culture system and provides superior attachment.Culture protocols initially called for daily media replacement. Especially with the first generation of feeder-free PSC culture media, any deviation from standard protocol could lead to increased spontaneous cell differentiation, slower growth rates, or down-regulation of pluripotency markers. Initial passages often looked fine, but changes became obvious during long-term culture with reduced feeding. Newer media formulations enable more flexibility in feeding schedules. This feature is frequently attributed to the substitution of native FGF-2 with thermostabilized versions of the growth factor. Our in-house data indicate, however, that the overall media composition and ability to provide a balanced and robust source of energy, nitrogen, amino acids and salts is at least if not more important in affording that flexibility. StemMACS iPS-Brew XF enables flexible feeding regimes, including the possibility of skipping one or two feeding days, and has been tested for maintenance of proliferation rate, pluripotent morphology and surface markers over 5 passages. Results of this analysis can be downloaded from the Related Resources panel to the right.
At a glance: Kits and reagents for passaging PSCs
Different PSC lines have different growth kinetics. Therefore, the optimal time and ratio for passaging must be determined individually for each cell line. Generally, it is good practice to keep cultures in a subconfluent state, where colonies are visibly separated. Split cultures before reaching confluency to avoid fusion of colonies and a rapid drop of growth factor levels.
A video showing various passaging techniques for PSC can be accessed from the Related Resources panel to the right.
Detachment of human PSCs must be gentle to maintain maximum viability. StemMACS Passaging Solution XF is designed to minimize cell culture manipulation, eliminating lengthy inactivation, dilution and centrifugation steps. The ready-to-use formulation facilitates a reproducible and standardized splitting procedure.
Human PSCs show decreased survival and attachment when colonies are dissociated into single cells or small cell clusters. ROCK inhibitors such as StemMACS Y-27632 or StemMACS Thiazovivin counter this effect and increase survival during passaging and thawing after cryopreservation (PMID: 17529971,20406903).
At a glance: Kits and reagents for the cryopreservation of PSCs
At a glance: Kits and reagents for the separation of PSCs
Efficient separation of undifferentiated PSCs. Pluripotent (TRA-1-60+) iPSCs were isolated from cultures containing spontaneously differentiated iPSCs grown on mouse embryonic feeder cells using the Anti-TRA-1-60 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells were fluorescently stained with Anti-TRA-1-60-PE and Anti-Feeder-APC after separation and analyzed by flow cytometry using the MACSQuant Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Human pluripotent stem cell lines can vary significantly with respect to their growth and differentiation characteristics. The genetic and epigenetic basis of this heterogeneity is still poorly understood and the subject of ongoing research (PMID: 23673969).Thorough and comprehensive characterization is therefore mandatory when establishing new ES or iPS cell lines and good practice during propagation of established lines. A typical base characterization includes assessment of morphology, extra- and intracellular marker expression, pluripotent differentiation potential, and karyotyping.
At a glance: Markers for the detection of undifferentiated human PSCs
In addition to pluripotency markers, antibodies that detect signs of early differentiation (e.g., Anti-SSEA-1 Antibodies) or the presence of feeder cells (e.g., Anti-Fibroblast or Anti-Feeder Antibodies) can complement the analysis. Especially with intracellular antigens, detection using conventional mono- or polyclonal antibodies has often been hampered by high background signals. Miltenyi Biotec REAfinity™ Recombinant Antibodies guarantee highly specific detection with low background signal. For details, see chapter Cell Analysis – Reagents.
The pluripotency and differentiation status of PSC cultures can be monitored by immunofluorescence microscopy or flow cytometry. The latter allows quantitative evaluation of culture composition and comparison of different cell lines and data points. A detailed protocol for flow cytometric quality control of pluripotent stem cell cultures with up to 6 markers can be downloaded from the Related Resources panel to the right.
At a glance: Kits and reagents for the assessment of PSC differentiation potential
|Directed differentiation||Differentiation of PSCs into ectoderm, mesoderm, and endoderm||StemMACS Trilineage Differentiation Kit, human|
|Flow cytometric analysis||Quantitative analysis of differentiated cells using REAfinity Antibodies||(clone: REA199)|
|Flow cytometric analysis||Quantitative analysis of differentiated cells using REAfinity Antibodies||CD140b-APC, human (clone: REA363)|
|Flow cytometric analysis||Quantitative analysis of differentiated cells using REAfinity Antibodies||CD184 (CXCR4)-APC, human (clone: REA649)|
|Flow cytometric analysis||Quantitative analysis of differentiated cells using REAfinity Antibodies||Anti-Sox17-Vio515, human (clone: REA701)|
|Flow cytometric analysis||Quantitative analysis of differentiated cells using REAfinity Antibodies||Anti-PAX-6-APC, human (clone: REA507)|
|Flow cytometric analysis||Quantitative analysis of differentiated cells using REAfinity Antibodies||Anti-Sox2-FITC, human and mouse (clone: REA320)|
Traditional assays to assess the differentiation potential of human PSCs include teratoma formation in mice and embryoid body formation in low attachment cell culture vessels. Both assays are time-consuming and difficult to reproduce and quantify.
An alternative is directed differentiation into derivatives of the ectodermal, mesodermal and endodermal lineages. However, to enable the comparison of different cell lines, the same differentiation procedure must be used for all cultures, with highly reproducible protocols and reagents. Miltenyi Biotec has developed the StemMACS Trilineage Differentiation Kit, human, which provides standardized, ready-to-use media for differentiation into ectoderm, mesoderm, and endoderm in 7 days. Combined with flow cytometry analysis of the resulting differentiated cells, this kit enables a quantitative comparison of the pluripotency of different PSC lines.A scientific poster describing the quantitative assessment of PSC differentiation potential, as well as a detailed protocol for the analysis of differentiated samples by flow cytometry can be downloaded from the Related Resources panel to the right.
At a glance: Kits and reagents for the dissociation of embryoid bodies
|Dissociation||Embryoid Body Dissociation Kit, human and mouse|
A variety of differentiation procedures have been developed to maximize yield of the desired differentiated target cells. The following is an overview of differentiation protocols known to work with feeder-free iPSC cultures using StemMACS iPS-Brew XF.
|Reagents to stimulate differentiation|
|Target cell type||Small Molecules||Cytokines||Reference (PMID)|
|Neuroectoderm||SB431542, LDN-193189, Y27632|
|Neural progenitors||CHIR99021, SB431542, compound E||Human LIF||28132834|
|Dopaminergic Progenitors||Thiazovivin, CHIR99021, SB431542, LDN-193189, Purmorphamine, DAPT||Human SHH, Human GDNF, Human BDNF||28094017|
|Neural Crest||SB431542, LDN-193189, Y27632||Human EGF, Human FGF-2||28762648|
|Peripheral Neurons||SB431542, LDN-193189, Y27632||Human EGF, Human FGF-2||28762648|
|Endothelial cells||Y27632, CHIR99021, Forskolin||Human VEGF||26214132|
|Cardiomyocytes||CHIR99021, IWR-1-endo||Application protocol|
|Pancreatic beta cells||CHIR99021, LDN-193189, Retinoic Acid, TPPB, Sant-1||Human FGF-7||23897760|
|Hepatic differentiation||Human Activin A, Human BMP-4, Human FGF-2, Human HGF, Human Oncostatin M||26586530|
|Alveolar differentiation||CHIR99021, SB431542, Dorsomorphin, IWR-1-endo, LY294002||Human Activin A, Human FGF-2, Human FGF-10, Human BMP-4, Human FGF-7||28802115|
At a glance: Kits and reagents for the separation of differentiated cells
|Target cell type||Starting material||Isolation strategy||Comments||Automation||Product|
|Neural crest||Single-cell suspension||Positive selection of target cells||Based on CD271 expression||Yes||Neural Crest Stem Cell MicroBeads, human|
|Dopaminergic progenitors||Single-cell suspension||Two-step positive selection of target cells||Based on IAP/ CD47 expression||Yes||CD47-PE, human and Anti-PE MicroBeads|
|Neuronal progenitors||Single-cell suspension||Positive selection of target cells||Based on PSA-NCAM expression||Yes||Anti-PSA-NCAM MicroBead Kit, human and mouse|
|Glial progenitors||Single-cell suspension||Positive selection of target cells||Based on A2B5 expression||Yes||Anti-A2B5 MicroBead Kit, human and mouse|
|Hematopoietic progenitors||Single-cell suspension||Positive selection of target cells||Based on CD34 expres||Yes||CD34 MicroBead Kit UltraPure, human|
|Cardiomyocytes||Single-cell suspension||Depletion of non-cardiomyocytes||Depletion cocktail||Yes||PSC-Derived Cardiomyocyte Isolation Kit, human|
|Endothelium||Single-cell suspension||Positive selection of target cells||Based on CD144 (VE-Cadherin) expression||Yes||CD144 (VE-Cadherin) MicroBeads, human|
|Definitive endoderm||Single-cell suspension||Positive selection of target cells||Based on CD184 (CXCR4) expression||Yes||CD184 (CXCR4) MicroBead Kit, human|